Novel Targeted Therapies in Hematologic Malignancies

Review expert perspectives on key findings on novel targeted therapies in hematologic malignancies presented at the 2017 ASH annual meeting.

Share

Program Content

Activities

  • Avadomide (CC-122) + Obinutuzumab in R/R NHL
    Phase Ib Study: Avadomide (CC-122) Plus Obinutuzumab in Relapsed/Refractory B-Cell NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • ACE-CL-003: Acalabrutinib + Obinutuzumab in CLL
    ACE-CL-003: Phase Ib/II Study of Acalabrutinib + Obinutuzumab in Patients With Untreated or R/R CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • MAVORIC: Mogamulizumab in CTCL
    Phase III MAVORIC: Mogamulizumab vs Vorinostat in Patients With Previously Treated CTCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

  • HERCULES: Caplacizumab in aTTP
    HERCULES: Caplacizumab in Adult Patients With Acquired Thrombotic Thrombocytopenic Purpura
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

  • Brentuximab Vedotin in CTCL
    Extended Follow-up From the ALCANZA Phase III Trial of Brentuximab Vedotin vs Methotrexate or Bexarotene for Previously Treated CD30-Positive CTCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

  • Avapritinib in Advanced Systemic Mastocytosis
    Phase I Study of KIT D816V Inhibitor Avapritinib (BLU-285) in Advanced Systemic Mastocytosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology